Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941879 | 0.89 | MAPT (0.50) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL2949549 | 0.83 | BCL2L1 (0.57) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL2951004 | 0.80 | BCL2L1 (0.65) | BCL2L1 | |
| SCHEMBL6991148 | 0.79 | BCL2L1 (0.57) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL2949663 | 0.79 | BCL2L1 (0.69) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL2943101 | 0.76 | MAPT (0.55) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL1542077 | 0.74 | MAPT (0.58) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL17937459 | 0.72 | BCL2L1 (0.65) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL1113832 | 0.72 | BCL2L1 (0.64) | BCL2L1MAPTPKMPOLBDOT1L | |
| SCHEMBL6987511 | 0.72 | BCL2L1 (0.54) | BCL2L1MAPTPKMPOLBDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885MAPT 4851/4885PKM 4646/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885MAPT 4830/4885PKM 4553/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885MAPT 4851/4885PKM 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.